Product Code: RP-ID-10086006 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086006
Market Overview:
Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2030
"The global migraine drugs market is anticipated to expand at a CAGR of 19% over the period 2022-2030, estimated to mark a revenue of USD 3 billion in 2021. The global migraine drug market has shown strong growth over the past few years. Migraine is a neurological disease that causes tingling or unilateral pain on the forehead, side of the head, or around the eyes. Pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia, and phonophobia. Migraine is usually diagnosed by examining the patients medical history and symptoms, as well as performing blood tests and magnetic resonance imaging (MRI) and computed tomography (CT) scans. Currently, over-the-counter (OTC) medications and prescription injections are available to relieve symptoms and reduce the frequency and severity of migraine attacks. These drugs are taken on a regular basis or during the onset or worsening of chronic pain.
The significant increase in migraine prevalence and diagnosis is one of the key factors driving market growth. In addition, improvements in migraine drug reimbursement policies and increased demand for precision drugs have also promoted market growth.
In addition, the demand for neuroelectric stimulation devices for the treatment of migraine is increasing, and new drugs with higher clinical efficacy are expected to be approved at an advanced stage, such as the introduction of monoclonal antibodies against peptides related to migraine genes. Calcitonin (CGRP). , Is also driving the growth of the market.
In addition, trials of migraine drugs for the treatment of coronavirus disease (COVID-19) are expected to have a positive impact on market growth. For example, the clinical-stage biopharmaceutical company Biohaven Pharmaceutical Holding Company Ltd., which is studying Zavegepant for the treatment of acute migraine, has begun clinical trials with the same drug to reduce the neuroimmune consequences of COVID-19 patients.
However, due to social distancing regulations, the reduction in clinic visits and migraine surgical treatments has affected the growth of the market.
KEY MARKET:
Kenneth Research provides an analysis of the main trends in each sub-segment of the global migraine drug market report, as well as global, regional and country-level growth forecasts during the period 2022-2030. Our report categorizes the market based on region, type of treatment, type of drug, route of administration, and distribution channel.
Breakdown by treatment type:
Abortion treatment breakdown by drug type Preventive treatment: triptan ergot alkaloid NSAIDs acetylcholine inhibitor/neurotoxin Ditans mAbs CGRP Other breakdown by route of administration: Oral injection Other breakdown by distribution channel: Hospital pharmacy retail pharmacy other.
COMPETITION LANDSCAPE:
The report also analyzes the market competition landscape of some major players, such as Abbott Laboratories, Allergan (AbbVie), Amgen, AstraZeneca, PhD Health (formerly Valeant) Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited."
Amgen Biopharmaceuticals, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline
Related Reports
Proof of Quality & Reliability
